|
|
Content Section
|
Self-Administered Drug Exclusion Directive
|
Article
for Self-Administered Drug Exclusion Directive - Medical Policy
Article (A23213) |
Contractor Information |
| |
Contractor
Name |
National
Government Services, Inc. |
Contractor
Number |
00308 |
Contractor
Type |
FI |
|
Article Information |
| |
Article
ID Number |
A23213 |
Article
Type |
SAD Exclusion
Article |
Key
Article |
No |
Article
Title |
Self-Administered
Drug Exclusion Directive - Medical Policy Article |
AMA CPT / ADA CDT Copyright Statement |
CPT codes, descriptions and other data only are
copyright 2007 American Medical Association (or such other
date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS
Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors
and other data contained therein) is copyright by the American
Dental Association.© 2002, 2004 American Dental Association.
All rights reserved. Applicable FARS/DFARS apply. |
| |
Primary Geographic Jurisdiction |
Connecticut
Delaware
New York - Entire State
|
Secondary Geographic Jurisdiction |
Connecticut
Delaware
New York
|
Original
Article Effective Date |
09/01/2004 |
Article
Revision Effective Date |
11/14/2007 |
Article
Text |
Self-Administered
Drug Exclusion Directive
This article replaces the one that was posted to the National
Government Services, Inc. Web site on 07/25/2007. This listing will only have noncovered determinations per the Centers for Medicare & Medicaid
Services (CMS) requirement. This
listing will be updated as necessary when new decisions are made
on excluded self-administered drugs.
The CMS issued the Self-Administered Drug Exclusion Program
Memorandum, Change Request 2200, on August
1, 2002. The directive instructed each Medicare carrier
to establish a process, modeled along CMS guidelines, to determine the exclusion from
Medicare coverage of those drugs, which were deemed usually self-administered,
even though they may have been previously covered under “incident
to” provisions. This notification is National Government Services,
Inc.’s response to the CMS instructions. The details of the Medicare process
can be viewed at http://www.cms.hhs.gov/transmittals/downloads/AB02139.pdf
under Reference File AB-02-72. The list of drugs identified includes
those which are administered “incident to” a physician’s service,
and more importantly, those drugs that will not be covered
or will no longer be covered “incident to” a physician service,
because they have been deemed by National Government Services,
Inc. to be “usually self-administered” by the patients who take
them.
The Process
Reliable statistical information on the extent of self-administration
by the patient may not always be available. In the absence of
such data, drugs delivered intravenously should be presumed to
be not usually self-administered by the patient. Absent evidence
to the contrary, drugs delivered by intramuscular injection may
be presumed to be not usually self-administered by the patient,
although the depth and nature of the particular intramuscular
injection may be considered in applying this presumption. Absent
evidence to the contrary, drugs delivered by subcutaneous injection
will be presumed to be self-administered by the patient, although
National Government Services, Inc. will consider other factors
such as acuteness of condition and frequency and duration of
injection.
For the purposes of applying this exclusion, the term “usually
self-administered” means self-administered more than 50 percent
of the time for all Medicare beneficiaries who receive the drug,
while not inpatients in a hospital, skilled nursing facility
(SNF) or other facility. If a drug is self-administered more
than 50 percent of the time, the drug is excluded from coverage,
and National Government Services, Inc. will make no payment for
it. The determination of exclusion or coverage is on a drug-by-drug
basis, and not on a beneficiary-by-beneficiary basis.
National Government Services, Inc. arrived at a single determination
for each drug by reviewing each indication and its route of administration
for that indication. The relative contribution for each indication
to the total use of that drug (i.e., weighted average) was obtained
in order to arrive at the overall status of administration. Hypothetically,
if a drug has three indications, and for the first indication
which makes up 30 percent of the use, the drug is usually self-administered,
while the second and third indications, which make up collectively
70 percent of the use, the drug is not usually self-administered,
then the drug would be determined overall to be not usually self-administered.
Consequently, this drug would be payable incident to a physician’s
service under Medicare self-administered exclusion provisions.
Conversely, if a different drug has two indications, and for
the first indication, which comprises 60 percent of the use,
it is usually self-administered, and for the remaining 40 percent
use of the drug, it is not usually self-administered, then the
overall determination would be that the drug is usually self-administered.
In this case, the drug would be excluded from coverage under
Medicare self-administered guidelines.
For a certain injectable drug, it is
“apparent on its face value” by the nature of the condition(s)
for which the drugs is administered, or the usual course of treatment
for specific conditions (chronic vs. acute), what the usual mode
of administration is. For example, Medicare deems a treatment
course of injections lasting less than two weeks, regardless
of frequency of injection or route, as acute. It would be unlikely
that the patient would self-administer the drug. Therefore, the
drug would be covered under Medicare self-administered exclusion
provisions. For other injectable medications,
it may be apparent by the usual and customary route of administration
that the drug would be covered (IV, IM medications).
Definitions/Clarifications
In applying this exclusion process, National Government Services,
Inc. utilized the following definitions and clarifications:
The term usually, as applied in this decision means more
than 50 percent of the time for all Medicare beneficiaries who
are within the National Government Services, Inc. jurisdiction,
who are not facility inpatients and to whom the drug is administered.
Consequently, a drug is “usually” self-administered when more
than 50 percent of the time the beneficiary injects him or herself.
Self-administered means administered by the patient to
him or herself, and does not include administered by spouses,
nursing aides, allied health professionals, or physicians.
Incident to the provider’s service means that the provider
or nurse practitioner be personally present for the administration
of the drug.
Medicare will only pay for the drug if the drug is administered
incident to a provider service, AND it has already been deemed usually not self-administered.
This coverage does not establish a universal Medicare
prescription coverage plan.
This coverage process only applies to the consideration of whether
a drug is usually self-administered, and not to whether it is
medically necessary. Drugs that are deemed not to be usually
self-administered may still not be covered/payable if they do not meet all medical necessity
criteria.
Places of service appropriate for this benefit are office (11)
and home (12) if the physician or qualified non-physician practitioner
is present, or the outpatient hospital (22). Inpatient hospital
administration of drugs is not included in this benefit, and
is not included in the determination of whether or not a drug
is self-administered.
The physician must purchase the drug. If the drug is purchased
by the beneficiary and then administered by the physician, the
drug will not be covered.
Drugs administered by a home health agency nurse are not reimbursable
under these provisions.
Evidentiary criteria utilized in arriving at National Government
Services Inc.’s specific determinations include, but not exclusively
or collectively, peer reviewed medical literature, standards
of medical practice, evidence-based practice guidelines, FDA-approved
label, and package inserts.
Drugs administered other than by injection (i.e., topically,
or as suppositories or via inhalers) are assumed to be self-administered
and are not covered under this benefit.
Implementation
The publication date of this list and any subsequent additions
to the list begins a 45-day notice period. National Government
Services, Inc., during this time, will maintain current existing
medical review and payment procedures. After the 45-day period,
National Government Services, Inc. will deny payment for “Not
Covered” drugs on this list, subject to the terms of this notice.
The list will be regularly reviewed and updated.
Appeals/Comments
For a particular drug, if a beneficiary’s claim is denied because
the drug is subject to the “self-administered drug” exclusion,
the beneficiary may appeal the denial. In cases where National
Government Services, Inc. has deemed a drug usually self-administered,
and therefore not covered, and an individual beneficiary appeals
the denial on grounds that he or she does not self-administer
the drug, it should not be assumed that the National Government
Services, Inc. decision would be overturned, once the appeal
is made. An Advance Beneficiary Notice (ABN) is not required in this case since this a “benefit
category” denial (i.e., a denial based on the fact that there
is no benefit category under which the drug may be covered) and
not a denial based on medical necessity. The physicians or providers
may bill the beneficiary for an excluded drug. Providers, billing
for an excluded drug, may wish to provide beneficiaries with
a Notice of Exclusion from Medicare Benefits (NEMB) (form CMS-20007), available
on the CMS Web site at: http://www.cms.hhs.gov/BNI/Downloads/CMS20007English.pdf . Additionally,
providers accepting assignment may appeal a denial under provisions
found in Publication 100-04, Medicare Claims Processing Manual,
Chapter 29, Section 310. Providers, as part of an appeal, should
submit to National Government Services, Inc. practice pattern
evidence and/or scientific literature to support the potential
overall reversal of National Government Services Inc.’s position
on a particular drug. A hospital may also appeal a denial under
Section 3781.2 of the Medicare Intermediary Manual to its fiscal
intermediary.
Comments may be directed to:
National Government Services, Inc.
Medical Policy Unit (Maine office)
Routing Code: ME0105-E070
P.O. Box 4767
Syracuse, NY 13221-4767
Attn: Martha Milton
Reference: Change Request 2200, Transmittal AB-02-072, CR
2311, Transmittal AB-02-139 |
Coverage
Topic |
Prescription
Drugs
|
|
Coding Information |
| |
Revenue
Codes:
Contractors may specify
Revenue Codes to help providers identify those Revenue Codes
typically used to report this service. In most instances
Revenue Codes are purely advisory; unless specified in the
article services reported under other Revenue Codes are equally
subject to this coverage determination. Complete absence
of all Revenue Codes indicates that coverage is not influenced
by Revenue Code and the article should be assumed to apply
equally to all Revenue Codes. |
Revenue codes will be listed in the appropriate
drug coverage article.
0024
- The Revenue code, Form Locator (FL) 42, Record Type (RT) 60,
field 5), (SV201), must contain revenue code 0024. This code
indicates that this claim is being paid under the PPS. This revenue code can
appear on a claim only once. CMS Publication 100-04,
Medicare Claims Processing Manual, Chapter 3, Section 140.3
When
coding PPS bills for ancillary
services
associated
with
a
Part
A
inpatient
stay,
the
traditional
revenue
codes
will
continue
to
be
shown
in
FL
42,
e.g.,
0250
-
Pharmacy,
042x
-
Physical
Therapy,
in
conjunction
with
the
appropriate
entries
in
Service
Units,
FL46
and
Total
Charges,
FL47. CMS Publication 100-04, Medicare
Claims
Processing
Manual,
Chapter
3, Section 140.3.
Please
note that not all revenue codes apply to every type of bill code.
Providers are encouraged to refer to the Fiscal Intermediary
Shared System (FISS) revenue code file for allowable bill types.
Similarly,
not all revenue codes apply to each CPT/HCPCS code. Providers are
encouraged to refer to the FISS HCPCS file for allowable revenue
codes.
Revenue
codes only apply to providers who bill these services to the
fiscal intermediary. Revenue codes do not apply to physicians,
other professionals and suppliers who bill these services to
the carrier.
|
|
Coding Table Information |
| |
CPT/HCPCS Codes - Table Format |
Code |
Descriptor Generic Name |
Descriptor Brand Name |
Exclusion Effective Date |
Exclusion End Date |
Comments |
J0135 |
INJECTION,
ADALIMUMAB, 20 MG |
Humira |
06/02/2004 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, weekly or every
other week. |
J0270 |
INJECTION,
ALPROSTADIL, 1.25 MCG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED
UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR
USE WHEN DRUG IS SELF ADMINISTERED) |
Caverject, Edex |
06/02/2004 |
N/A |
Usually
self-injected by patient on an "as needed basis". |
J0275 |
ALPROSTADIL
URETHRAL SUPPOSITORY (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED
UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR
USE WHEN DRUG IS SELF ADMINISTERED) |
Muse |
06/02/2004 |
N/A |
Supposistory. |
J0630 |
INJECTION,
CALCITONIN SALMON, UP TO 400 UNITS |
Calcimar, Miacalcin |
06/02/2004 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, daily or every
other day. |
J1324 |
INJECTION,
ENFUVIRTIDE, 1 MG |
Fuzeon |
12/28/2007 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, twice daily. |
J1438 |
INJECTION,
ETANERCEPT, 25 MG (CODE MAY BE USED FOR MEDICARE
WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF
A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED) |
Enbrel |
06/02/2004 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, usually twice
a week. |
J1595 |
INJECTION,
GLATIRAMER ACETATE, 20 MG |
Copaxone |
06/02/2004 |
N/A |
Self-administration;
subcutaneous 20 mg/day. |
J1675 |
INJECTION,
HISTRELIN ACETATE, 10 MICROGRAMS |
Supprelin |
12/28/2007 |
N/A |
Non-acute
subcutaneous administration, usually once daily by patient. |
J1815 |
INJECTION,
INSULIN, PER 5 UNITS |
Humalog, Humulin, Iletin, Insulin Lispo, Novo Nordisk,
NPH, Pork Insulin, Regular Insulin, Ultralente, Velosulin, Humulin R, Iletin II Regular
Port, Insulin Purified Pork, Relion, Lente Iletin I, Novolin R, Humulin R U-500 |
06/02/2004 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, every day. |
J1817 |
INSULIN
FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS |
Humalog, Humulin, Vesolin BR, Iletin II NPH
Pork, Lantus, Lispro-PFC, Novolin, Novolog, Novolog Flexpen, Novolog Mix, Relion Novolin |
06/02/2004 |
N/A |
Non-acute
chronic filling of pump by patient. |
J1830 |
INJECTION
INTERFERON BETA-1B, 0.25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED
UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR
USE WHEN DRUG IS SELF ADMINISTERED) |
Betaseron |
06/02/2004 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, usually every
other day. |
J2170 |
INJECTION,
MECASERMIN, 1 MG |
Increlex, Iplex |
06/02/2004 |
N/A |
Non-acute
subcutaneous injection twice daily by patient. |
J2354 |
INJECTION,
OCTREOTIDE, NON-DEPOT FORM FOR SUBCUTANEOUS
OR INTRAVENOUS INJECTION, 25 MCG |
Sandostatin |
06/02/2004 |
N/A |
Usually
self-administered injections two to four times daily,
depending on the indication. |
J2940 |
INJECTION,
SOMATREM, 1 MG |
Protropin |
06/02/2004 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, several time
a week. |
J2941 |
INJECTION,
SOMATROPIN, 1 MG |
Genotropin |
06/02/2004 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, several time
a week. |
J3030 |
INJECTION,
SUMATRIPTAN SUCCINATE, 6 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED
UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR
USE WHEN DRUG IS SELF ADMINISTERED) |
Imitrex |
06/02/2004 |
N/A |
Subcutaneous
(SC) injection by patient at onset of symptoms (up to
two times in a 24-hour period). |
J3110 |
INJECTION,
TERIPARATIDE, 10 MCG |
Forteo |
12/28/2007 |
N/A |
Non-acute,
subcutaneous (SC) injection into thigh or abdomen (lower
stomach area) once a day by patient using multidose prefilled
delivery device (FORTEO pen - contains 28 daily doses). |
J3490 |
UNCLASSIFIED
DRUGS |
Byetta (exenatide) |
12/28/2007 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, within the 60-minute
period before morning and evening meals. |
J3490 |
UNCLASSIFIED
DRUGS |
Symlin (Pramlintide acetate) |
12/28/2007 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, immediately prior
to major meals. |
J3590 |
UNCLASSIFIED
BIOLOGICS |
Kineret |
12/28/2007 |
N/A |
Non-acute
subcutaneous (SC) injection by patient, every day. |
J3590 |
UNCLASSIFIED
BIOLOGICS |
| | | | |